CAGAS
SRPT icon

Capital Advisory Group Advisory Services’s Sarepta Therapeutics SRPT Stock Holding History

Capital Advisory Group Advisory Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$4K – 570
2021
Q2 		$4K Buy
+50
New +$3.79K ﹤0.01% 480

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Advisory Group Advisory Services's SRPT Position: Q3 2021 in Review

Capital Advisory Group Advisory Services sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 50 shares — an estimated $4K sold.

Capital Advisory Group Advisory Services first reported a position in SRPT in Q2 2021 and held it in 1 quarter. The position peaked at $4K in Q2 2021. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • Capital Advisory Group Advisory Services reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Capital Advisory Group Advisory Services sold 50 Sarepta Therapeutics shares in Q3 2021, an estimated $4K.
  • Capital Advisory Group Advisory Services first reported a position in Sarepta Therapeutics in Q2 2021 and held it in 1 quarter.
  • Capital Advisory Group Advisory Services's Sarepta Therapeutics position peaked at $4K in Q2 2021.
  • 306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Capital Advisory Group Advisory Services's 13F filing for Q3 2021, filed 12 Nov 2021.